Debra Tompson1, Ruth Oliver-Willwong. 1. GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex, UK. debra.j.tompson@gsk.com
Abstract
OBJECTIVES: To explore the pharmacokinetic-pharmacodynamic relationship between systemic exposure to ropinirole and the primary efficacy end points from two phase 3 studies. METHODS: Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Monotherapy (101468/168) compared ropinirole 24-hour prolonged release with ropinirole immediate release in patients with early Parkinson's disease (PD). Efficacy And Safety Evaluation in Parkinson's Disease Adjunct (101468/169) compared ropinirole 24-hour prolonged release or placebo in patients with advanced PD not optimally controlled with L-dopa. Sparse blood samples were collected for pharmacokinetic evaluations through population analysis. The relationship between ropinirole systemic exposure [steady-state area under the curve between time zero and 24 hours after dose, AUC(0-24,ss)] and change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS) total motor score, and awake time spent off was investigated. RESULTS: In EASE-PD Monotherapy, the relationship between the decrease in UPDRS motor score and AUC(0-24,ss) was similar for both formulations, with a 60% to 80% probability of response for the exposure range studied. In patients with early PD, similar clinical benefit was achieved at AUC(0-24,ss) values associated with doses of 8 to 12 mg and higher doses (up to 24 mg). In EASE-PD Adjunct, the predicted probability of an off-time response for a patient on placebo was approximately 0.4, increasing to a near total probability of response rate (approximately 0.9) at higher systemic exposures of ropinirole 24-hour prolonged release. CONCLUSIONS: Characterization of the exposure-response relationship has identified that a dose range of 8 to 12 mg provides clinical benefit for the improvement in UPDRS total motor score in patients with early PD. Similarly, pharmacokinetic-pharmacodynamic analysis showed that, in patients with advanced PD, the probability of response increased with increasing exposures to ropinirole, indicating that doses more than 8 to 12 mg may lead to an improved benefit in parallel with reductions in L-dopa dose.
RCT Entities:
OBJECTIVES: To explore the pharmacokinetic-pharmacodynamic relationship between systemic exposure to ropinirole and the primary efficacy end points from two phase 3 studies. METHODS: Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Monotherapy (101468/168) compared ropinirole 24-hour prolonged release with ropinirole immediate release in patients with early Parkinson's disease (PD). Efficacy And Safety Evaluation in Parkinson's Disease Adjunct (101468/169) compared ropinirole 24-hour prolonged release or placebo in patients with advanced PD not optimally controlled with L-dopa. Sparse blood samples were collected for pharmacokinetic evaluations through population analysis. The relationship between ropinirole systemic exposure [steady-state area under the curve between time zero and 24 hours after dose, AUC(0-24,ss)] and change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS) total motor score, and awake time spent off was investigated. RESULTS: In EASE-PD Monotherapy, the relationship between the decrease in UPDRS motor score and AUC(0-24,ss) was similar for both formulations, with a 60% to 80% probability of response for the exposure range studied. In patients with early PD, similar clinical benefit was achieved at AUC(0-24,ss) values associated with doses of 8 to 12 mg and higher doses (up to 24 mg). In EASE-PD Adjunct, the predicted probability of an off-time response for a patient on placebo was approximately 0.4, increasing to a near total probability of response rate (approximately 0.9) at higher systemic exposures of ropinirole 24-hour prolonged release. CONCLUSIONS: Characterization of the exposure-response relationship has identified that a dose range of 8 to 12 mg provides clinical benefit for the improvement in UPDRS total motor score in patients with early PD. Similarly, pharmacokinetic-pharmacodynamic analysis showed that, in patients with advanced PD, the probability of response increased with increasing exposures to ropinirole, indicating that doses more than 8 to 12 mg may lead to an improved benefit in parallel with reductions in L-dopa dose.
Authors: Alison K Berger; Thomas Green; Steven J Siegel; Eric J Nestler; Ronald P Hammer Journal: Biol Psychiatry Date: 2010-10-30 Impact factor: 13.382
Authors: Paula Trujillo; Nelleke C van Wouwe; Ya-Chen Lin; Adam J Stark; Kalen J Petersen; Hakmook Kang; David H Zald; Manus J Donahue; Daniel O Claassen Journal: Cortex Date: 2019-01-29 Impact factor: 4.027
Authors: Daniel O Claassen; Adam J Stark; Charis A Spears; Kalen J Petersen; Nelleke C van Wouwe; Robert M Kessler; David H Zald; Manus J Donahue Journal: Mov Disord Date: 2017-06-19 Impact factor: 10.338
Authors: Adam J Stark; Christopher T Smith; Ya-Chen Lin; Kalen J Petersen; Paula Trujillo; Nelleke C van Wouwe; Hakmook Kang; Manus J Donahue; Robert M Kessler; David H Zald; Daniel O Claassen Journal: J Neurosci Date: 2018-02-26 Impact factor: 6.167
Authors: Peter A LeWitt; Werner Poewe; Lawrence W Elmer; Mahnaz Asgharnejad; Babak Boroojerdi; Frank Grieger; Lars Bauer Journal: Clin Neuropharmacol Date: 2016 Mar-Apr Impact factor: 1.592
Authors: Adam J Stark; Christopher T Smith; Kalen J Petersen; Paula Trujillo; Nelleke C van Wouwe; Manus J Donahue; Robert M Kessler; Ariel Y Deutch; David H Zald; Daniel O Claassen Journal: Neuroimage Clin Date: 2018-02-10 Impact factor: 4.881